Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)

This study is testing a combination treatment approach for locally advanced pancreatic cancer (cancer that can't be surgically removed but hasn't spread to distant organs) that combines radiation therapy adapted to tumor changes during treatment ("adapted SBRT"), chemotherapy, and a new immunotherapy drug called ivonescimab. **You may be eligible if...** - You are between 18 and 80 years old with confirmed unresectable locally advanced pancreatic cancer - Your cancer has at least one measurable tumor - You are in good functional health (able to carry out normal activities) - Your blood, kidney, and liver function are adequate **You may NOT be eligible if...** - Your cancer has spread to distant organs (metastatic) - You have prior radiation to the pancreatic area - You have active autoimmune disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.